BridGene Biosciences' IMTAC ™ Small Molecule Discovery Platform Featured in Multiple Presentations at 2021 AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics
Retrieved on:
Thursday, October 7, 2021
SAR, TEAD, Sunitinib, SAN, Transforming protein RhoA, Drug discovery, Conference, Liposarcoma, TCGA, Cell, Nm, Protein, Glioblastoma, Diagnosis, Cancer, Immortalised cell line, NF2, Education, American Association for Cancer Research, Entrepreneurship, The Cancer Genome Atlas, Factor X, ELISA, WDR5, AACR, GTPase, Stomach, CDH1, Gene expression, CEO, Mesothelioma, MLL1, American Association, Association, IC50, Disease, Patient, Science, DGC, Research, Technology, Pharmaceutical industry, Vaccine, Fine chemical, Mobile phone
The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
Key Points:
- The presentations detail the company's proprietary small molecule discovery platform, IMTACTM (Isobaric Mass Tagged Affinity Characterization) and its use in BridGene's latest discovery of therapeutic candidates and the identification of new targets for approved small-molecule drugs.
- "This is among the most prominent scientific gatherings addressing drug discovery and molecular targets.
- Overall, our presentations describe our IMTAC platform technology and its capabilities, the discovery of novel small-molecule inhibitors for undruggable targets, and the identification of previously unknown targets for approved small-molecule drugs."
- BridGene used the IMTAC platform to screen its unique covalent library against live-cell proteomes and discovered small-molecule ligands for WDR5.